Navigation Links
Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
Date:6/25/2008

ROCKVILLE, Md., June 26 /PRNewswire/ -- Pinnacle Biologics, a private, full service pharmaceutical and biotech solutions company, today announced that it has entered into a preferred stock purchase transaction with MedImmune, LLC, pursuant to which MedImmune has acquired certain unspecified number of preferred stock shares of Pinnacle Biologics, Inc. The terms of the agreement were not disclosed.

Pinnacle Biologics owns the marketing and distribution rights to MedImmune's Ethyol(R), 50 mg/ml, powder for solution for infusion in Western Europe, Turkey and Israel.

"This is a highpoint for Pinnacle, as it signifies an additional milestone for our company," said Guillermo Herrera, Chairman of the Board of Pinnacle Biologics.

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

Website: http://www.pinnaclebiologics.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1 (240) 372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pinnacle Biologics Announces Contract With Chiltern
2. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
3. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
4. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
5. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
6. Insmed to Present at CBI Follow-On Biologics Conference
7. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
8. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Ohio , Jan. 17, 2017  On January ... the 35th Annual J.P. Morgan Healthcare Conference in ... Joseph D. Kittle, Jr. , spoke to pharmaceutical leaders ... developed by ProclaRx to break down and destroy biofilms.  ... protect bacteria and prevent antibiotics and the body,s immune ...
(Date:1/14/2017)... ... January 14, 2017 , ... ... providing complete end-to-end genome assemblies to researchers around the globe. Long considered ... obstacle in answering a wide range of scientific questions. The announcement was ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci has been ... found among its diverse customer base. The latest entry in this field is ... including BTX and Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, ...
(Date:1/12/2017)... ... January 12, 2017 , ... Huffman Engineering, Inc. , a ... will work in the company’s Lincoln office as a chemical engineer. In his ... systems for customers in the life science manufacturing and water/wastewater industries. , Prior to ...
Breaking Biology Technology:
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Dec 15, 2016 ... Research and Markets has announced the addition of ... The report forecasts the global military biometrics market to ... The report has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):